All In Biotech

Drug Trial Radar · NCT01356498

Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout

Multicenter, Open Label Extension Study of 8 mg PEG-uricase in Subjects Who Completed Protocols C0405 or C0406 for Symptomatic Gout

Last checked: Nov 20, 2026Latest source record: Dec 2, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

151

Actual

Start

Dec 2006

Primary completion

Jan 2010

Study completion Jan 2010

Sponsor

Lead sponsor
Savient PharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 19, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label extension phase of two double-blind, placebo-controled Phase 3 protocols evaluating PEG-uricase in the treatment of hyperuricemic subjects with symptomatic gout. The purpose of this study is to provide a continuation of treatment to subjects completing the double-blind studies and obtain long-term safety and efficacy data.

Conditions

  • Gout

Interventions

  • pegloticaseBiological

    8 mg intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Uric Acid (mg/dL)Time frame: Week 13, Week 25, Week 53, Week 101

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Kaiser Permanente Medical Center, Clinical Trials Unit

    San Francisco, California

  • Pacific Arthritis Center Medical Group

    Santa Maria, California

  • Agilence Arthritis & Osteoporosis Medical Center

    Whittier, California

  • Veterans Affairs Medical Center

    Washington D.C., District of Columbia

  • Arthritis & Rheumatic Disease Specialties

    Aventura, Florida

  • Ocala Rheumatology Research Center

    Ocala, Florida

  • St. Petersburg Arthritis Center

    St. Petersburg, Florida

  • The University of Chicago

    Chicago, Illinois

  • Graves Gilbert Clinic

    Bowling Green, Kentucky

  • Peter A. Holt, M.D.

    Baltimore, Maryland

  • Center for Rheumatology and Bone Research

    Wheaton, Maryland

  • Justus J. Fiechtner, MD, PC

    Lansing, Michigan

  • CentraCare Clinic

    Saint Cloud, Minnesota

  • Rheumatology Associates of North Jersey

    Teaneck, New Jersey

  • Duke University Medical Center

    Durham, North Carolina

  • New Horizons Clinical Research

    Cincinnati, Ohio

  • The Ohio State University

    Columbus, Ohio

  • STAT Research, Inc.

    Dayton, Ohio

  • David R. Mandel, MD, Inc.

    Mayfield Village, Ohio

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania

  • Mid Atlantic Research Assoc.

    Philadelphia, Pennsylvania

  • Arthritis Northwest, PLLC

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.